Scarica l'app Stockscreener
22.19
5.37%
1.13
Dopo l'orario di chiusura:
22.00
-0.19
-0.86%
Precedente Chiudi:
$21.06
Aprire:
$21.18
Volume 24 ore:
467.86K
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.27B
Reddito:
$10.00M
Utile/perdita netta:
$-377.74M
Rapporto P/E:
-2.628
EPS:
-8.4436
Flusso di cassa netto:
$-172.35M
1 W Prestazione:
-3.65%
1M Prestazione:
-14.75%
6M Prestazione:
+19.17%
1 anno Prestazione:
+143.58%
Intervallo 1D:
$21.18
$22.72
Intervallo di 1 settimana:
$19.76
$24.08
Portata 52W:
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
22.19 | 1.21B | 10.00M | -377.74M | -172.35M | -8.4436 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Hedge Fund Moves: Will Zenas BioPharma Inc benefit from geopolitical trends2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.5%Should You Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Wall Street Recap: What are Zenas BioPharma Inc.’s technical support levels - baoquankhu1.vn
ENAVATE Sciences Increases Zenas BioPharma Holding to 28% of PortfolioNews and Statistics - IndexBox
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch - The Motley Fool
Analyst Downgrade: Will Zenas BioPharma Inc outperform during market ralliesMarket Sentiment Summary & Growth Focused Investment Plans - baoquankhu1.vn
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Wedbush reiterates Zenas BioPharma (ZBIO) outperform recommendation - MSN
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis - TipRanks
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
HC Wainwright Forecasts Lower Earnings for Zenas BioPharma - MarketBeat
A Look At Zenas BioPharma (ZBIO) Valuation As Losses Widen And Going Concern Risks Emerge - Sahm
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Zenas BioPharma (ZBIO) Is Down 9.4% After Non-Dilutive Funding And Shelf Filing UpdateHas The Bull Case Changed? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Citigroup Issues Pessimistic Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
ZBIO: HC Wainwright & Co. Reiterates Buy Rating with $44 PT | ZB - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results - MarketBeat
Zenas BioPharma price target raised to $55 from $45 at Guggenheim - TipRanks
BioPharma Credit to Invest $125 Million in Zenas BioPharma - marketscreener.com
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares - Yahoo Finance
Biopharma Credit enters senior secured loan agreement with Zenas BioPharma for up to $125 mln - marketscreener.com
Biopharma Credit Enters Senior Secured Loan Agreement With Zenas Biopharma For Up To $125 Mln - TradingView
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma - TipRanks
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 - AlphaStreet
Zenas BioPharma (ZBIO) EPS Loss Narrows To US$2.05 Tests Growth Focused Bullish Narratives - simplywall.st
Zenas BioPharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Guggenheim raises Zenas Biopharma stock price target to $55 on pipeline progress - Investing.com Canada
New Zenas BioPharma hires receive 235,700 options, 33,450 RSUs - Stock Titan
Zenas BioPharma, Inc. ($ZBIO) Founder, CEO and COB 2025 Pay Revealed - Quiver Quantitative
Zenas BioPharma Reports 2025 Financial Results, Advances Obexelimab for IgG4-RD and SLE, Secures $250M Pharmakon Financing - Minichart
Morgan Stanley raises Zenas Biopharma stock price target on IgG4-RD outlook - Investing.com Canada
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.2%What's Next? - MarketBeat
Zenas BioPharma 2025 Annual Report: Advancing Obexelimab and I&I Therapies, Clinical Milestones, and Strategic Partnerships - Minichart
[ARS] Zenas BioPharma, Inc. SEC Filing - Stock Titan
Zenas BioPharma (NASDAQ: ZBIO) plans 2026 virtual meeting, director votes - Stock Titan
Zenas BioPharma 2025 10‑K: $10.0M revenue, GAAP loss $8.44/share - TradingView
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share - marketscreener.com
Obexelimab Phase 3 success anchors Zenas BioPharma (ZBIO) immunology pipeline - Stock Titan
Zenas reports $10.0M revenue, $377.7M net loss for FY2025; cash $360.5M - TradingView
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoYZenas BioPharma (NASDAQ:ZBIO) - Benzinga
Zenas BioPharma (Nasdaq: ZBIO) widens 2025 loss but lines up $250M Pharmakon financing - Stock Titan
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):